ReviewMicrobiology spectrum2016
Diabetes and Tuberculosis.
Review in Microbiology spectrum, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 4 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Type 2 diabetes mellitus associated microRNAs in tuberculosis susceptibility: a systematic review and bioinformatic analysis.Frontiers in endocrinology · 2026Pooled it
- Integrating tuberculosis and noncommunicable diseases care in low- and middle-income countries (LMICs): A systematic review.PLoS medicine · 2022Pooled it
- Diabetes among tuberculosis patients and its impact on tuberculosis treatment in South Asia: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- The epidemiology of tuberculosis-associated hyperglycemia in individuals newly screened for type 2 diabetes mellitus: systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- The Effects of Oral Liposomal Glutathione and In Vitro Everolimus in Altering the Immune Responses againstBiomolecular concepts · 2021Trial
- Effects of Oral Liposomal Glutathione in Altering the Immune Responses AgainstFrontiers in cellular and infection microbiology · 2021Trial
- Tuberculosis- and Diabetes Mellitus-Associated Knowledge, Stigma, and Health-Seeking Behaviour in Ghana.International journal of environmental research and public health · 2026Article
- Decoding the shared genetic liability of lower respiratory tract infections via genomic structural equation modeling.BMC pulmonary medicine · 2026Article
- Mycobacterium tuberculosis IDH-PPARγ interaction suppresses GPX4 to drive macrophage ferroptosis and sustain persistent infection.Nature communications · 2026Article
- Acute Endobronchial Dissemination of a Tuberculoma Following EBUS-GS-Guided Transbronchial Biopsy: A Case Report.Respirology case reports · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- Article
- Diabetes mellitus, TB, and HIV multi-morbidities among adults in Uganda.Public health action · 2026Article
- Article
- A putativeFrontiers in immunology · 2026Article
- Interplay between biological & social vulnerability and poor tuberculosis treatment outcome in Brazil: a nationwide study using multivariate modelling with excess risk.Lancet regional health. Americas · 2026Article
- Latent TB infection in solid organ transplant recipients in Serbia: A single center experience from a low TB burden country.PloS one · 2026Article
- Sensitivity and specificity of tuberculosis screening tools in people with diabetes.PLOS global public health · 2026Article
- ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteria.Cell reports · 2025Article
- Sodium-glucose transport protein 2 inhibitor use in diabetes and its association with tuberculosis incidence.BMC medicine · 2025Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The increase in type 2 diabetes mellitus (DM) patients in countries where tuberculosis (TB) is also endemic has led to the reemerging importance of DM as a risk factor for TB. DM causes a 3-fold increase in TB risk and a 2-fold increase in adverse TB treatment outcomes. Given the sheer numbers of DM patients worldwide, there are now more TB patients with TB-DM comorbidity than TB-HIV coinfection. There is an urgent need to implement strategies for TB prevention and control among the millions of DM patients exposed to Mycobacterium tuberculosis. This chapter summarizes the current epidemiological, clinical, and immunological knowledge on TB and DM and their clinical and public health implications. These include the underlying mechanisms for TB risk in DM patients and their clinical and sociodemographic characteristics that distinguish them from TB patients without DM. TB-DM comorbidity is posing a new challenge for integrating the short-term care for TB with the long-term care for DM, particularly in low- and middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.